Digital therapeutics company Kaia Health is partnering with Italian pharma firm Chiesi Group to commercialize its chronic obstructive pulmonary disease (COPD) rehabilitation app in Europe.
Read more: Hexoskin Smart Shirt Accurately Measures Breathing, Could be Useful for Monitoring COPD
The agreement marks one of the first times in respiratory care that a digital therapeutics company and pharmaceutical company are partnering to bring patients a digital therapeutic that supports COPD treatment outcomes through behavior change, rather than relying on pharmacology.
“Our strategic partnership with Chiesi, a growing global company with an established European commercial presence, brings a wealth of experience in navigating the respiratory health landscape in Europe, while expanding patient access to evidence-based, digital physical pulmonary rehabilitation,” said Konstantin Mehl, Founder and President, Kaia Health. “The entire Kaia Health team is excited to join forces with Chiesi to enhance COPD patient care and quality of life through digital therapeutics”.
COPD is a long-term condition that causes inflammation in the lungs, damaged lung tissue and a narrowing of the airways, making breathing difficult. It is an enormous cost for healthcare systems in Europe.
Under the partnership arrangement, the evidence-backed Kaia Health COPD digital therapeutic, which delivers a personalized, physical pulmonary rehabilitation experience, will be highly focused on key markets in Europe., Chiesi Group said in a press release.
The Kaia COPD solution consists of a mobile app-based software program, accessed via an iOS or Android smartphone or tablet, and an interface for motivational support that can be delivered by a provider such as health coaches or healthcare professionals. It digitizes and delivers affordable, accessible, physical Pulmonary Rehabilitation - an essential component of COPD treatment - directly to patients' homes on their smartphone. The app also delivers comprehensive education and customized daily training sessions, along with mindfulness and stress relief exercises, augmented with human coaching support and individualized therapy. The Kaia COPD solution has been investigated in one pilot trial and is currently the subject of an ongoing RCT in Europe. The Kaia Health COPD app is CE Marked in Europe as a Class 1 medical device.
Kaia Health is a member of the Digital Therapeutics Alliance (DTA), an international non-profit trade association of industry leaders and stakeholders engaged in the evidence-driven advancement of digital therapeutics.
Read more: Spry Health’s the Loop System Wearable Gets FDA Clearance for Monitoring COPD Patients
“We’re pleased to partner with Kaia Health to complement and further strengthen our portfolio in the respiratory therapeutic area, expanding our ability to address patient care through a non-pharmacological approach” said Ugo Di Francesco, Chief Executive Officer of the Chiesi Group. “This agreement embodies Chiesi’s commitment to providing the highest level of care and quality of life possible for people living with COPD and other respiratory diseases, going beyond merely those issues addressable through medication. We have been impressed with Kaia Health’s experience to date bringing impactful digital solutions to the European market and are looking forward to helping European COPD patients benefit from their expertise”.
